


COVID-19 y Embarazo:

Lo que en Medicina Reproductiva queremos saber

Carlos Simón, M.D., Ph. D.

Professor of Obstetrics & Gynecology, University of Valencia. Spain
Senior Lecturer PT, BIDMC Harvard University, Boston, MA, USA
Adjunct Clinical Professor, Baylor College of Medicine, Houston, TX, USA
Founder and Head of the Scientific Advisory Board, Igenomix



Igenomix[®]
foundation FORWARD
THINKING



UNIVERSITAT
DE VALÈNCIA

Learning Objectives

- ✓ COVID-19 disease and SARS- Cov-2 virus
- ✓ Lessons from previous Coronavirus epidemics
- ✓ COVID-19 and Pregnancy
- ✓ Recommendations from Ob/Gyn professional bodies & Reproductive Medicine Societies

COVID-19 is the Coronavirus Disease caused by the **SARS-CoV-2 virus**, declared as a new **pandemic** by the World Health Organization (WHO) as of 11th March, 2020.




Current situation in Spain (March 25, 2020)

Worldwide
375,498 cases

Europe
216,771 cases

Spain
47,610 cases

3,434 deceased
5,377 cured



Fuente: RENAVE.ISCIII-CCAES

Current situation in the United States (March 25, 2020)


Worldwide
375,498 cases

Europe
216,771 cases

United States
54,453 cases


737 deceased

States Reporting Cases of COVID-19 to CDC*



Coronavirus pandemics in the 21st century

Coronaviruses are a group of viruses causing illness ranging in severity from the common flu to fatal outcome.



In the 21st century, three coronaviruses have crossed the species barrier to cause deadly pneumonia in humans:

- Severe acute respiratory syndrome coronavirus (SARS-CoV)
- Middle-east respiratory syndrome coronavirus (MERS-CoV)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

The recurrent spillovers suggest that future zoonotic transmission events may continue.

Drosten et al. *N Engl J Med.* 2003; Ksiazek et al. *N Engl J Med.* 2003; Li et al. *Science.* 2005; Zaki et al. *N Engl J Med.* 2012; Ge et al. *Nature.* 2013; Menachery et al. *Nat Med.* 2015; Yang et al. *Virus Res.* 2015; Menachery et al. *Proc Natl Acad Sci U S A.* 2016; Zumla et al. *Nat Rev Drug Discov.* 2016; Anthony et al. *Virus Evol.* 2017; Hu et al. *PLoS Pathog.* 2017; Huang et al. *Lancet.* 2020; Zhou et al. *Nature.* 2020; Zhu et al. *N Engl J Med.* 2020;

Comparison of recent coronaviral pandemics

	COVID-19	SARS	MERS
Virus	Betacoronavirus SARS-CoV-2	Betacoronavirus SARS-CoV	Betacoronavirus MERS-CoV
Origin	Wuhan, China	Guandong, China	Saudi Arabia
Onset	December 2019	November 2002 - July 2003	June 2012 - still active
Spread	194 countries	31 countries	27 countries
Cases	375,489 reported	8,422 reported	2,494 reported
Deaths	12,784	916	858
Reproductive no.	≈3	≈2-3	≈1
Age av (range)	59 (10-89) years	40 (1-91) years	50 (1-94) years
Sex ratio (M:F)	56:44	43:57	64.5:35.5%
Mortality	Currently estimated 1%*	9.6%	35-40%


Epidemiology of SARS-CoV-2

- Incubation period – average of 5 days (range of 2-14 days)
- Sex – males more most affected than females
- Age – average 49-56 years among hospitalized patients, children rare
- Underlying illness – fever, cough, myalgia, headache, diarrhea
- Case fatality rate – 1% (preliminary)

Transmission



- Person-to-person – between people who are in close contact with one another (within ~6 feet) via respiratory droplets produced when an infected person coughs or sneezes
- Other forms of transmission (e.g., from infected surfaces or objects) might be possible
- Hospital-associated transmission playing a key role

Identification Methods




SARS-CoV-2 virus

SARS-CoV-2 is a single-stranded RNA, enveloped virus, belonging to the β -coronavirus family. This virus is able to enter the human cells by binding of its spike (S) protein to ACE2 enzyme.



ACE2 (Angiotensin converting enzyme 2) is expressed in the membrane of different cell types as a part of the renin-angiotensin (RAS) system, involved in the regulation of blood pressure.

ACE2 and Renin-Angiotensin System



- The main role of ACE2 is the degradation of Ang II resulting in the formation of angiotensin 1-7 (Ang 1-7) which opposes the actions of Ang II.
- Ang-(1-7) is then able to bind to its Mas receptor in the cell membranes.
- ACE2 has a beneficial role in many diseases such as hypertension, diabetes, and cardiovascular disease where its expression is decreased.
- Current therapeutic strategies for ACE2 involve augmenting its expression using ACE2 adenoviruses, recombinant ACE2 or compounds to produce organ protection.


SARS-CoV-2 virus infection

Cell

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

- SARS-CoV-2 infection depends on the host cell factors ACE2 and TMPRSS2.
- The cellular Serine Protease TMPRSS2 is essential in priming SARS-CoV-2 S-protein for entry.
- Camostat mesylate, a clinically proven inhibitor of TMPRSS2, blocks SARS-CoV infection in lungs cells.
- Antibodies against SARS-CoV spike (S-protein) may offer some protection against SARS-CoV-2.

Article




Detection of ACE2 and RAS system

RAS system has been found to be key for physiological functions in different organs and tissues....

Tissue	Physiological Role of RAS
Blood vessel	Vasomotor regulation, oxidative metabolism
Heart	Vasomotor tone, fibrotic regulation, oxidative metabolism
Kidney	Blood pressure regulation
CNS	Sympathetic regulation of blood pressure
Adipose tissue	Adipogenesis
Eye	Aqueous humor dynamics
Liver	Glucose metabolism

Nehme et al. *J Cardiovasc Dev Dis.* 2019.

...being also important for reproductive physiology



Pan et al. *Int J Mol Sci.* 2013.

Detection of ACE2 and RAS system in reproductive organs

OVARY: May be involved in follicular development, steroidogenesis, oocyte maturation, ovulation and atresia.

- ACE2 is present in human ovaries
- Gonadotropin induces changes in ovarian expression of ACE2.
- ACE2 participates in ovarian physiology through Ang-(1-7).

TESTIS: It may participate in spermatogenesis.

- ACE2 is only expressed by Leydig cells.
- Men with severe spermatogenesis defects present lower levels of ACE2, Ang-(1-7) and MasR than fertile men.

UTERUS: Possible roles in implantation and parturition are unknown

- ACE2 is expressed in endometrial epithelium of reproductive-age women, increasing in the secretory phase.
- ACE2 mRNA is highly expressed in decidua and placenta, amnion and chorion.

Detection of SARS-CoV-2 in reproductive organs


Four SARS patients defined by WHO criteria: 3 men (25, 38 and 57 years) and 1 woman (62 years).

Organs and tissues	A1061 ^b		A1062 ^b		A1065 ^b		A1076 ^b	
	IHC	ISH	IHC	ISH	IHC	ISH	IHC	ISH
Lung	+++	+++	+++	+++	+++	+++	+++	+++
Stomach	++	++	+	+	+	+	+	+
Small intestine	++	++	+	+	+	+	+	+
Kidney	++	++	++	++	++	++	++	++
Adrenal	++	++	++	++	++	++	++	++
Skin	++	++	++	++	++	++	++	++
Parathyroid	++	++	++	++	++	++	++	++
Pituitary	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+
Cerebrum	+	+	+	+	+	+	+	+
Pancreas	+	+	+	+	+	+	-	-
Oesophagus	-	-	-	-	-	-	-	-
Bone marrow	-	-	-	-	-	-	-	-
Thyroid	-	-	-	-	-	-	-	-
Spleen	-	-	-	-	-	-	-	-
Lymph node	-	-	-	-	-	-	-	-
Cerebellum	-	-	-	-	-	-	-	-
Heart	-	-	-	-	-	-	-	-
Striated muscle	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-
Uterus	-	-	-	-	-	-	-	-

Gu et al: “The testes of the seven male patients displayed focal atrophy. However, SARS viral sequences and viral particles were not identified”.

Lessons from previous Coronavirus epidemics

SARS and Pregnancy



SARS and Pregnancy

MATERNAL COMPLICATIONS:

- High mortality (all from the Hong Kong study, 25%).
- Equivalent clinical and laboratory signs in pregnant vs. non-pregnant women.
- Pregnant patients required more ICU admissions compared to non-pregnant women.
- Increased spontaneous miscarriage in first Hong Kong study.

FETAL and NEONATAL COMPLICATIONS:

- 35% PTB associated with neonatal morbidity (80% in first Hong Kong study).
- Increased IUGR, intrauterine demise, and neonatal death.
- Placental weight reduction and thrombosis is related to the duration of SARS before delivery.

TRANSMISSION:

- Unlikely vertical transmission of SARS-CoV, either transplacental or perinatal.
- Absence of virus and viral particles in the POC or neonates.
- Negative RT-PCR and viral culture of newborn's nasopharyngeal and throat swabs, gastric aspirate, urine, meconium and later stool, amniotic fluid, cord blood, placenta, and breast milk.

SARS and Pregnancy

OPEN QUESTIONS:

Causes of miscarriage:

- Severe maternal respiratory failure and hypoxemia may disrupt uterine placental flow
- Use of Ribavirin:
 - 1st and 2nd trimester infected patients not treated with ribavirin had uncomplicated pregnancies
 - Ribavirin is embryo lethal and teratogenic effects found in animal studies

Cause of fetal complications:

- Severe maternal respiratory illness
- Decreased oxygen supply to the fetus
- Severe maternal debilitating illness


Recommendations for patient management:

- Theoretical advantage of delaying delivery to avoid exposure to virus at birth.
- Transplacental passage of SARS-CoV antibodies to fetal circulation may protect the fetus/neonate.

CONCLUSIONS:

The adverse pregnancy outcomes might be due to the effects of SARS infection on pregnancy as well as to the medical treatment received for SARS.

MERS and Pregnancy



Park et al. Korean J Anesthesiol. 2016. Alfaraj SH et al. J Microbiol Immunol Infect. 2019; Alserehi et al. BMC Infect Dis. 2016; Assiri et al. Clin Infect Dis. 2016; Malik et al. Emerg Infect Dis. 2016; Payne et al. J Infect Dis. 2014; Racelis et al. Western Pac Surveill Response J. 2015; Jeong et al. J Korean Med Sci. 2017.

MERS and Pregnancy

MATERNAL COMPLICATIONS:

- 23% mortality (3 cases).
- Equivalent clinical and laboratory signs in pregnant vs. non-pregnant women.
- 7 patients were admitted to ICU and 5 required mechanical ventilation.
- 5 emergency C-sections.
- 1 preeclampsia
- 8 women recovered and had healthy neonates.

FETAL and NEONATAL COMPLICATIONS:

- 1 stillbirth and 1 neonatal death.
- 2 placental abruption.
- No evidence of relationship between MERS-CoV and placental disorder.

TRANSMISSION:

- Negative RT-PCR and antibody tests in newborn's nasopharyngeal swabs and peripheral blood and placenta.
- Fetal specimen and/or placenta were not available for evaluation in the most cases.

MERS and Pregnancy

OPEN QUESTIONS:

It is unclear whether MERS directly or indirectly produce stillbirth or preterm birth.

Role of maternal treatment in miscarriage and PTB:

- patients were treated with Ribavirin after babies were born.

CONCLUSIONS:

Various factors may have contributed to the successful outcome of MERS patients:

- Young age
- MERS presentation late in pregnancy (also 2 patients infected at 1st trimester)

One pregnant patient using ART with no obstetric complications delivered a healthy neonate.

Animal models of Coronavirus infection – SARS and MERS

Although many animal models have been developed for the study of SARS and MERS, no information is available about their effects on reproductive function and the fetus.

Studies have been focused on the effects on:


- Lung
- Heart
- Liver
- Brain

Species	Virus	
	SARS-CoV	MERS-CoV
Humans	<ul style="list-style-type: none"> • Clinical signs include fever and respiratory illness. • Lung pathology is consistent with pneumonia and acute lung injury. 	<ul style="list-style-type: none"> • Clinical signs include fever and respiratory illness. Some patients develop renal failure. • Lung pathology samples are not available for investigation.
NHP	<ul style="list-style-type: none"> • Rhesus macaques, cynomolgus macaques, African green monkeys and common marmosets are susceptible to infection. Clinical signs, viral replication and pathology depend on the species. 	<ul style="list-style-type: none"> • Rhesus macaques develop a transient infection with moderate viral replication and pathology in the lung. • Common marmosets have a more severe response to the virus with higher viral titers and severe pathology in the lungs. Lethality is also observed in this model.
Mice	<ul style="list-style-type: none"> • Young inbred mice (BALB/c, C57BL6, 129S) support viral replication but fail to show clinical signs of disease. • Older inbred mice (BALB/c), knockout mice (STAT 1^{-/-}, Rag 1^{-/-}, CD1^{-/-}, Beige) and transgenic mice (K18-hACE2, A70-hACE2) develop generalized illness, robust viral growth and pronounced lung pathology consistent with pneumonia and acute lung injury. The K18-hACE2 transgenic mice develop central nervous system disease, which is not a feature in humans. 	<ul style="list-style-type: none"> • Inbred mice are not naturally susceptible to infection. • Transduced mice (Ad5-hDPP4) develop clinical signs and support replication of virus with interstitial pneumonia and viral antigen found in the lungs. • Transgenic mice (hCD26/DPP4) develop robust respiratory and generalized illness with high viral titers and extensive inflammation in the lungs. Lethality was also observed in this model.
Hamsters	<ul style="list-style-type: none"> • Clinical illness (measured by a decrease in activity on the exercise wheel) is accompanied by viral replication and pronounced histopathological changes such as inflammation, pneumonitis and consolidation in the lungs. 	<ul style="list-style-type: none"> • <u>Hamsters do not support replication.</u>
Ferrets	<ul style="list-style-type: none"> • Clinical illness (fever and sneezing), is accompanied by viral replication and histologic changes in the lungs. 	<ul style="list-style-type: none"> • Ferrets do not support replication.
Rabbits	<ul style="list-style-type: none"> • The rabbit model has not been investigated. 	<ul style="list-style-type: none"> • The rabbit model is currently under investigation.

Gretebeck and Subbarao. Curr Opin Virol. 2015; Gong and Bao. Animal Model Exp Med. 2018.


Animal models of Coronavirus infection – COVID-19

No evidence about the effect of SARS-CoV-2 infection in the non-human primate model (Rhesus macaques)



COVID-19 and Pregnancy

COVID-19 and Pregnancy



COVID-19 and Pregnancy

MATERNAL COMPLICATIONS (in 43 patients):

- Pre-eclampsia in 2 cases.
- Premature rupture of membranes reported in 5 cases.
- Chorioamnionitis in 1 case.

- All the patients in these studies were treated with antiviral drugs AFTER delivery.

FETAL and NEONATAL COMPLICATIONS:


- 1 baby died with multiple organ failure and disseminated intravascular coagulation.
- Fetal distress reported in 8 cases.
- Oligohydramnios and polyhydramnios reported in 2 cases.

COVID-19 and Pregnancy

VERTICAL TRANSMISSION?

- No reported evidence of vertical transmission. Negative tests for ALL the samples tested:
 - nasopharyngeal, oropharyngeal and throat swabs
 - gastric aspirate
 - urine
 - feces
 - plasma and/or peripheral blood
 - amniotic fluid
 - umbilical cord blood
 - Placenta
 - breast milk
- Throat swab from dead neonate also tested negative for SARS-CoV-2 virus
- Media news from 2 cases of neonates positive for SARS-CoV-2 with no evidence of infection before, during or after delivery.(???)

COVID-19 and reproductive outcomes



No significant differences in:

- Intraoperative blood loss
- Birth weight
- Fetal distress
- Meconium-stained amniotic fluid
- Preterm birth
- Neonatal asphyxia

Reasons for caution when analysing COVID-19 and SARS-CoV-2

1. Limited availability of reliable scientific data due to the novelty of the pandemic.
2. Potential duplication of reported COVID-19 cases.
3. Lack of evidence of the effect of coronaviruses on reproductive function in animal models of COVID-19, SARS and MERS.



Editorial Concern—Possible Reporting of the Same Patients With COVID-19 in Different Reports

Howard Bauchner, MD; Robert M. Golub, MD; Jody Zylke, MD

Since January 1, 2020, JAMA and the JAMA Network journals have received hundreds of manuscripts and direct queries related to coronavirus disease 2019 (COVID-19), including research reports, case series and case reports, and opinion pieces. The editors have become aware that some of the patients described in some of these manuscripts, sometimes with overlapping authorship, have been reported in more than 1 submission. This inclusion of the same patients in more than 1 report has not been clearly indicated in the submitted manuscripts. This is of concern and may represent a lapse in ethical standards of scientific reporting.¹



Viewpoint



Related article

Reporting of the same patients in different articles (without clear indication of the duplicate reporting) creates an inaccurate scientific record, may affect the accuracy of subsequent estimates of prevalence of the disease or outcomes, and may preclude valid meta-analyses, unless authors of the

meta-analyses are able to obtain individual patient data to ensure that patients are not being counted more than once in any publication.

The potential for harm that could accrue from this type of misleading reporting is particularly concerning for studies of COVID-19. They are related to a rapidly evolving pandemic with only limited information available for decision-making, so that inaccurate data and analyses not only affect understanding the disease and its epidemiology, but have the potential to result in inappropriate changes in clinical care, ineffective public health responses, exacerbations of the economic consequences from this epidemic, and increasing anxiety about the pandemic.

We recognize the important efforts of authors in rapidly communicating information about COVID-19 to the clinical and scientific community. However, we urge all authors of reports related to COVID-19 to clearly identify if any patients in any submitted manuscript have been reported in any previous submissions or publications.

<https://jamanetwork.com/journals/jama/fullarticle/2763371>

Recommendations from Ob/Gyn professional bodies & Reproductive Medicine Societies

WHO testing recommendations

Laboratory testing strategy recommendations for COVID-19

Interim guidance
22 March 2020



Global surveillance for COVID-19 caused by human infection with COVID-19 virus

Interim guidance
20 March 2020



- All countries should increase their level of preparedness, alert, and response to identify, manage, and care for new cases of COVID-19; laboratory testing is an integral part of this strategy.
- Any persons meeting the criteria for testing should be tested for COVID-19 infection using available molecular tests.

Countries that have not yet reported cases Countries dealing with sporadic cases Considerations for countries dealing with clusters of cases

WHO recommends that all suspect cases be tested for COVID-19

Countries dealing with community transmission

Laboratories will need to be prepared for the significant increase in the number of specimens that need to be tested for COVID-19. Testing constraints should be anticipated, and prioritization will be required.

[https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-\(2019-ncov\)](https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov))
https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf

American College of Obstetrics and Gynecology (ACOG) & British Royal College of Obstetricians and Gynaecologists (RCOG)

Specific guidance for pregnant women based on limited experience with SARS-CoV and MERS-CoV

- Compared to the general population, pregnant women may be at higher risk of:
 - Severe illness
 - Morbidity or mortality
 - Adverse perinatal outcomes, including preterm birth
- There is little historical information available for women considering pregnancy or embarking on ART.
- Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially mitigate risk may be required, which will inevitably impact overall success rates.

<https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Novel-Coronavirus2019>

<https://www.rcog.org.uk/coronavirus-pregnancy>

Chen et al. Lancet 2020; Zhu et al. Transl Pediatr. 2020.

Coronavirus Covid-19: ESHRE Statement on Pregnancy and Conception: March 14th, 2020

“There is no strong evidence of any negative effects of Covid-19 infection on pregnancies, especially those at early stages, as indicated by the latest updates from the Centers for Disease Control and Prevention (CDC) in the USA and others in Europe.”

PATIENT'S MANAGEMENT

As a precautionary measure - and in line with the position of other scientific societies in reproductive medicine - we advise that:

1. **All fertility patients** considering or planning treatment, **even if they do not meet the diagnostic criteria for Covid-19 infection**, should avoid becoming pregnant at this time.
2. For those **patients already having treatment**, we suggest considering deferred pregnancy with oocyte or embryo freezing for later embryo transfer.
3. **Patients who are pregnant or those (men and women) planning or undergoing fertility treatment** should avoid travel to known areas of infection and contact with potentially infected individuals.

ASRM Patient Management and Clinical Recommendations during the Coronavirus (COVID-19) Pandemic: March 17th, 2020

“Given the information we do have, while it would be wise for individuals with confirmed or presumed COVID-19 infection to avoid pregnancy, there appears to be no cause for alarm for those already pregnant.”

PATIENT'S MANAGEMENT

1. **Suspend initiation of new treatment cycles**, including ovulation induction, intrauterine inseminations (IUIs), in vitro fertilization (IVF) including retrievals and frozen embryo transfers, as well as non-urgent gamete cryopreservation.
2. Strongly consider **cancellation of all embryo transfers** whether fresh or frozen.
3. Continue to care for patients who are currently “in-cycle” or who require urgent stimulation and cryopreservation.
4. Suspend elective surgeries and non-urgent diagnostic procedures.
5. Minimize in-person interactions and increase utilization of telehealth.
6. **Patients with active COVID-19 should not undergo fertility treatment**, unless they require urgent fertility preservation.

Reactions to the ASRM Patient Management and Clinical Recommendations



The Fertility Providers Alliance (FPA) that represents over 400 fertility specialists, requested ASRM to revisit and reshape its recommendations to the reproductive endocrinology community, based in 3 reasons:

1. The actual public health burden created by the continuation of fertility care

The vast majority of fertility centers across USA are free-standing medical facilities that operate without hospital affiliation.

2. The classification of infertility treatment as 'non-urgent' or elective

The reproductive health community has fought diligently to recognize infertility for what it is: a disease state that includes many diverse medical conditions.

3. The harmful consequences of an indeterminate delay in access to care

For these patients, "revisiting guidelines periodically as the pandemic evolves" creates an anguishing and indeterminate state of reproductive limbo.

Conclusions

- ✓ LIFE FIRST
- ✓ In the postpandemic era, safe reproduction should be based in scientific and clinical knowledge.
- ✓ More than ever scientific research is needed in our field for the benefit of our patients and we are accountable for it.



Inmaculada Moreno, PhD
Felipe Vilella, PhD
Xavi Santamaria, MD, PhD
Jaime Herrero

+



FINANCIAL SUPPORT



Unión Europea
Fondo Europeo de
Desarrollo Regional
"Una manera de hacer Europa"



Our Igenomix team



Spain (HQ)

Scientists
 AL-ASMAR, NASSER
 ALONSO VALERO, ROBERTO
 AMADOZ NAVARRO, ALICIA
 BAÚ, DAVIDE
 BLESÀ JARQUE, DAVID
 BOVER CATALÀ, ANA
 CAMPOS GALINDO, INMACULADA
 CERVERO SANZ, ANA CRISTINA
 CLEMENTE CISCAR, MONICA
 DE LA FUENTE LUCENA, EMILIO
 DIEZ JUAN, ANTONIO
 GARCIA HERRERO, SANDRA
 GARCIA PASCUAL, M. CARMEN
 GIL SANCHIS, CLAUDIA
 GOMEZ DE LA CRUZ, CARLOS ALFONSO
 GOMEZ SANCHEZ, EVA MARIA
 HERNANDEZ DE DIEGO, RAFAEL
 HERVAS LORENTE, ARANTXA
 JIMENEZ ALMAZAN, JORGE
 RODRIGUEZ, JULIO CESAR
 MARTINEZ CONEJERO, JOSE ANTONIO
 MARIN LOPEZ DE CARVAJAL, LUCIA
 MARIN VALLEJO, CARLOS
 MATEU BRULL, EMILIA
 MILAN SANCHEZ, MIGUEL
 MIR PARDO, PERE
 MIRAVET VALENCIANO, JOSE ALBERTO
 MORENO GIMENO, INMACULADA
 NAVARRO GAYA, ROSER
 NAVARRO SANCHEZ, LUIS
 PEINADO CERVERA, MARIA VANESSA
 RINCON BERTOLIN, ALEJANDRO
 RODRIGO VIVO, LORENA
 RUBIO LLUESA, CARMEN
 RUIZ ALONSO, MARIA
 SANCHEZ PIRIS, MARIA ISABEL

SANTA MORENO, LAURA
 SANTAMARIA COSTA, JAVIER
 SANZ SALVADOR, LUCIA
 SIMON VALLES, CARLOS
 VALBUENA PERILLA, DIANA

Technicians
 AGUILA CLARES, BEGOÑA
 AYALA ALVAREZ, GUSTAVO LEONARDO
 BARRERO, DESIRE
 BERMELL JUNCOS, SOLEDAD
 BOSCH IBAÑEZ, ALVARO
 BURGOS LUJAN, INES
 CENTELLES PASTOR, VICENTE
 COLOMA MARCO, MARIA DOLORES
 ESCOBEDO LUCEA, MILAGROS
 ESCORCIA MORA, PATRICIA
 FERRO BARBERO, AZARINA
 GALVEZ VIEDMA, MARTA
 GARCIA MORENO, MIRIAM
 GOMEZ LOPEZ, MARIA
 HERRERO BAENA, MARIA
 IÑIGUEZ QUILES, LAURA
 MADRIGAL GIMENEZ, TANIA
 MARTINEZ BENITO, TANTRA
 MARTINEZ ESCRIBANO, SEBASTIAN
 MARTINEZ FERNANDEZ, M. ASUNCION
 MARTINEZ MERINO, LUCIA
 MATEOS GREGORIO, PABLO
 MOLES SELMA, SARA
 MORATA GARCIA, MARIA JESUS
 NIETO ALFANI, JESSICA
 PEREZ SORIANO, CRISTINA
 PERIS PARDO, LAURA
 POZO CRUZ, ANA MARIA
 SANCHEZ GONZALEZ, ESTELA
 SILVESTRE IVARS, MARIA
 TERUEL IZQUIERDO, VANESA
 VELERT CARRION, GEMMA

USA & Canada

Scientists
 AKINWOLE, ADEDYOIN
 CINNIUGLU, CENGIZ
 DARVIN, TRISTAN
 HAGHI, GHAZAL
 HARTON, GARY
 JAKUBOWSKA MILENA
 KAYALI, REFIK
 MAE HOOVER, LARISSA
 PHILLIPS, KIMBER
 SNEIDER, ALYSSA
 STANKEWICZ, TIFFANY
 YEH, CHRISTINE

Technicians
 ALVAREZ, INALVIS
 BAUTISTA, ABELARD
 BOJI NESCU, ANCA
 DUENAS, FRANCISCO
 CUI, KATHY
 GRIFFIN, MARISA
 LAYNE, NICOLE
 LOANIDIS, ALEXANDROS
 NGUYEN, VI
 PENA, DAYTERNA
 PHAM, QUON
 SANTI, ANNAI
 SEN, GURKAN
 SHAIBI, DEREK
 TUYEN, KENNY



Mexico

Scientists
 COYOTECATL, CRISTINA
 POO LLANILLO, MARIA EUGENIA

Technicians
 MORALES BECERRIL, KARLA JENESSES
 OROZCO PANTOJA, MARITZA

Brazil

Scientists
 AYALA, CAMILA
 COPRERSKI, BRUNO
 CUZZI, JULIANA
 DA MOTA, PRISCILA
 DE OLIVEIRA, PRISCILA
 DO CARMO, GABRIEL
 ESTEVES MORAES, CAMILA
 GLORIA, THIAGO
 MOARES, CAMILA
 PEREIRA, KEITTY
 RIBOLDI, MARCIA
 UEHARA DE SOUZA, MARIANE

Argentina

Scientists
 LOPEZ IGLESIAS, PILAR
 RIVADENEIRA, ANDREA

UK

Scientists
 MUTLU, AYLIN
 NAJA, ROY
 RABERI, ARAZ
 THORNHILL, ALAN

Italy

Scientists
 CAPALBO, ANTONIO
 GIRARDI, LAURA
 PATASSINI, CRISTINA
 ROMANELLI, VALERIA

Technicians
 GIANCANI, ADRIANO
 MORETTO, MARTINA

UAE

Scientists
 CHOPRA, RUPALI

Technicians
 ALNIMS, HAYA
 ROY CHOWDGHURY, SHEWETA
 SHARMA, SHEWETA
 WARRIER EDAKUNNY, SHRUTI

India

Scientists
 KHAJURIA, RAJNI
 SINGH BUTTAR, BRINDERJIT

Technicians
 UPADHYAY, DIVYESH

China

Scientists
 CHANG, ANDY
 HSU, HANSIU
 MATSUOKA, TOSHIKI

Technicians
 ARAI, CHIHIRO
 ICHIKAWA, ERIKO
 MIYAZAWA, MAKI

Colaborators:

